echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JCC: Can patients with inflammatory bowel disease terminate the treatment of hydrogenated pine when receiving Inflixi single anti-maintenance therapy?

    JCC: Can patients with inflammatory bowel disease terminate the treatment of hydrogenated pine when receiving Inflixi single anti-maintenance therapy?

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    BACKGROUND: Prescription drugs for hydrocodiosis can reduce the risk of antibody formation in patients treated with infringic bowel disease (IBD) in infrifflixi monoantigen (IFX).
    researchers conducted a series of studies to determine the safety of hydrogenated pre-flux drugs in IBD patients with a sustained clinical response after receiving IFX maintenance treatment.
    Method this is an observational prospective drug clinical study that includes patients who are continuous IBD outpatients who have no IFX infusion response in the past, and IBD patients who maintain IFX clinical remission (individual or combined therapy) for at least 6 months.
    followed the queue for a year after they stopped taking prescription drugs for hydrogenated pine.
    of the 268 IBD outpatients, 95 met the inclusion criteria (average age 38 years; 64 percent for men; 80 percent for Crohn's disease, 45 percent for hormone and IFX combined therapy).
    ifX duration was 5 years, the average infusion dose was 533 mg, and the average interval duration was 7.9 weeks.
    adverse events with permanent ATIs or infusion-related reactions in patients within 1 year.
    four patients had a short-lived ATIs and no clinical response.
    there was no significant difference in infrifflixi monoantitic serum levels (5.5 μg / mL and 5.9 μg / mL) measured during 3 IFX infusions before and after the suspension of the drug hydrocodulation.
    response rate to IFX in the last year was 18%.
    concluded that in IBD patients who continued clinical remission in IFX maintenance therapy, hydrocodiosis was safe.
    this study shows that patients with long-term remission under IFX maintenance treatment do not need to routinely use hydrocodyclycerides for routine treatment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.